United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Adcetris Ph3 TLR.

Pfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Amazon

Costco

Hershey

Target

Walmart

Dividends move in and out of fashion every few investment cycles. But, patient investors and study after study has made one thing clear: over the long run dividend stocks tend to outperform the market.

The Absolute Best Dividend Stocks I'm Buying In March

Chevron

Kenvue

Plains All American Pipeline

AT&T

Universal Corp

Are you ready for retirement? Planning for retirement can be overwhelming, that's why it could be a good idea to speak to a fiduciary financial advisor about your goals today.

Looking To Start Earning Passive Income in March? Here Are 6 Top Dividend Stocks

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID business. During a four-hour investor event last week, Pfizer pushed its initative to “accelerate breakthroughs that help people with cancer globally live better and longer lives,” according to CNBC.

Pfizer bets on cancer drugs to recover from rapid decline of COVID business

Viatris

Pfizer's slumping revenue is a temporary hiccup considering its incredibly deep pipeline. Viatris has made important changes to its business that should pay off down the road.

2 Dirt Cheap Dividend Stocks to Buy and Hold

AbbVie

Ginkgo Bioworks Holdings

Pfizer is a rebound candidate that pays a hefty dividend while you wait. AbbVie has been broadening its product offerings to become more diversified.

3 Pharmaceutical Stocks to Buy Hand Over Fist in March

Walgreens

Just because a stock's price fell does not mean it will stay down forever. Pfizer has a long roadmap for how to regain its recent glory.

1 Bruised Dividend Stock to Buy While It's Cheap, and 1 to Avoid

Amgen

Novo Nordisk

The catalyst for top weight-loss stocks comes down to one sweeping attribute: a burgeoning total addressable market. According to a Goldman Sachs analysis, earlier last year, the global industry for anti-obesity medications (AOMs) reached $6 billion on an annualized basis.

Obesity Drugs 2024: The Skinny on the Top 3 Weight-Loss Stocks

Teladoc

The pharmaceutical and telehealth industries are on impressive growth trajectories. Pfizer is implementing a multiyear growth plan and is already off to a strong start.

Have $2,000? 2 Magnificent Stocks Ready for a Bull Run

The pharmaceutical giant has been trying to shore up investor sentiment after its shares fell more than 40% in 2023.

Pfizer is betting big on cancer drugs to turn business around after Covid decline – here's what to know

Gilead Sciences

Novartis

Gilead is diversifying its business, and yet the stock trades near recent lows and pays a solid dividend. Novartis has a new look with its spinoff of Sandoz but remains a solid pick for income investors.

3 Dividend Stocks to Buy Hand Over Fist in March

British American Tobacco

Kinder Morgan

Main Street Capital

Whirlpool

A financial advisor can help you understand the advantages and disadvantages of investment properties.

6 Absolutely Best Dividend Stocks Yielding Over 6%

Structure Therapeutics Inc

Viking Therapeutics

Contenders are beginning to emerge from the lab, some with the potential to unseat Lilly's Zepbound and Novo's Wegovy.

Wegovy and Zepbound Are King. Who's Coming for Their Crowns.

Best Buy

Kohl's

Sabra Health Care

TC Energy

The company offers medicines and vaccines in various therapeutic areas, including: Cardiovascular metabolic and women's health under the Premarin family and Eliquis brands Biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands Sterile injectable and anti-infective medicines and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

6 Bargain Dividend Stocks To Buy

Canadian Pacific Kansas City Limited

Extra Space Storage

Raytheon Technologies

Market sentiment is bullish but not at extreme levels, suggesting unusual developments in market sentiment, with surprisingly loose financial conditions.

Beware Of Low Returns! Here Are 4 Dividend Stocks With Over 12% Annual Return Potential

Pfizer's stock has plummeted by nearly 55% from its all-time high, but it remains a solid company with potential for considerable upside. Technical indicators suggest that Pfizer's stock has likely found a bottom and could begin a new long-term uptrend.

Pfizer: A Strong Buy Trading Below A 10 P/E Ratio

Pfizer's stock is still reeling from the decline of its coronavirus-related sales. At least one Wall Street analyst thinks that it has a bright future.

1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?

Altria

SL Green Realty

Cohen & Steers Infrastructure Fund Inc

Verizon

The markets had a good week, with the S&P 500 increasing by 0.84% and the Dow Jones jumping 1.59%.

Dividend Harvesting Portfolio Week 157: $15,700 Allocated, $1,389.49 In Projected Dividends

Bristol-Myers

Disney

Intel

PayPal

If you're searching for must-have stocks for wealth, look no further. In investing, identifying the right stocks leads to a fear of missing out.

Millionaire's Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town

News for Pfizer Stock (PFE)